Tags

Type your tag names separated by a space and hit enter

Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach.
Biomed Res Int. 2020; 2020:2683286.BR

Abstract

Background

A new endemic disease has spread across Wuhan City, China, in December 2019. Within few weeks, the World Health Organization (WHO) announced a novel coronavirus designated as coronavirus disease 2019 (COVID-19). In late January 2020, WHO declared the outbreak of a "public-health emergency of international concern" due to the rapid and increasing spread of the disease worldwide. Currently, there is no vaccine or approved treatment for this emerging infection; thus, the objective of this study is to design a multiepitope peptide vaccine against COVID-19 using an immunoinformatics approach.

Method

Several techniques facilitating the combination of the immunoinformatics approach and comparative genomic approach were used in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the envelope protein of 2019-nCoV as a target.

Results

Extensive mutations, insertion, and deletion were discovered with comparative sequencing in the COVID-19 strain. Additionally, ten peptides binding to MHC class I and MHC class II were found to be promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99%, respectively.

Conclusion

The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target. Nevertheless, the proposed vaccine rapidly needs to be validated clinically in order to ensure its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks.

Authors+Show Affiliations

Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan.Faculty of Medicine, Alneelain University, Khartoum, Sudan.Department of Biotechnology, University of Bahri, Khartoum, Sudan.Department of Molecular Biology, National University Biomedical Research Institute, National University, Khartoum, Sudan.Department of Microbiology, International University of Africa, Khartoum, Sudan.Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan.Department of Biotechnology, University of Bahri, Khartoum, Sudan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32461973

Citation

Abdelmageed, Miyssa I., et al. "Design of a Multiepitope-Based Peptide Vaccine Against the E Protein of Human COVID-19: an Immunoinformatics Approach." BioMed Research International, vol. 2020, 2020, p. 2683286.
Abdelmageed MI, Abdelmoneim AH, Mustafa MI, et al. Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. Biomed Res Int. 2020;2020:2683286.
Abdelmageed, M. I., Abdelmoneim, A. H., Mustafa, M. I., Elfadol, N. M., Murshed, N. S., Shantier, S. W., & Makhawi, A. M. (2020). Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. BioMed Research International, 2020, 2683286. https://doi.org/10.1155/2020/2683286
Abdelmageed MI, et al. Design of a Multiepitope-Based Peptide Vaccine Against the E Protein of Human COVID-19: an Immunoinformatics Approach. Biomed Res Int. 2020;2020:2683286. PubMed PMID: 32461973.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. AU - Abdelmageed,Miyssa I, AU - Abdelmoneim,Abdelrahman H, AU - Mustafa,Mujahed I, AU - Elfadol,Nafisa M, AU - Murshed,Naseem S, AU - Shantier,Shaza W, AU - Makhawi,Abdelrafie M, Y1 - 2020/05/11/ PY - 2020/02/29/received PY - 2020/04/20/accepted PY - 2020/5/29/entrez PY - 2020/5/29/pubmed PY - 2020/6/3/medline SP - 2683286 EP - 2683286 JF - BioMed research international JO - Biomed Res Int VL - 2020 N2 - Background: A new endemic disease has spread across Wuhan City, China, in December 2019. Within few weeks, the World Health Organization (WHO) announced a novel coronavirus designated as coronavirus disease 2019 (COVID-19). In late January 2020, WHO declared the outbreak of a "public-health emergency of international concern" due to the rapid and increasing spread of the disease worldwide. Currently, there is no vaccine or approved treatment for this emerging infection; thus, the objective of this study is to design a multiepitope peptide vaccine against COVID-19 using an immunoinformatics approach. Method: Several techniques facilitating the combination of the immunoinformatics approach and comparative genomic approach were used in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the envelope protein of 2019-nCoV as a target. Results: Extensive mutations, insertion, and deletion were discovered with comparative sequencing in the COVID-19 strain. Additionally, ten peptides binding to MHC class I and MHC class II were found to be promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99%, respectively. Conclusion: The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target. Nevertheless, the proposed vaccine rapidly needs to be validated clinically in order to ensure its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/32461973/Design_of_a_Multiepitope_Based_Peptide_Vaccine_against_the_E_Protein_of_Human_COVID_19:_An_Immunoinformatics_Approach_ L2 - https://doi.org/10.1155/2020/2683286 DB - PRIME DP - Unbound Medicine ER -